USFDA completes Biocon Telangana plant inspection,no observations issued
New Delhi: Biotechnology major Biocon Monday said the US health regulator has completed the inspection of its Telangana manufacturing facility without making any observations.
"The United States Food and Drug Administration (USFDA) conducted a good manufacturing practice (GMP) inspection of our active pharmaceutical ingredients (APIs) manufacturing facility at Telangana from December 12-14, 2018," Biocon said in a regulatory filing Monday.
The inspection was concluded without any observations and no Form 483 was issued, the company added.
A Form 483, is issued by the USFDA to notify a company's management of any objectionable condition at its manufacturing facility. The form is issued after completing the inspection.
Also Read: USFDA completes inspection of Biocon Bengaluru plant with no observations
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd